Studies in mice showed that a whole-body KO of IFN-β worsens EAE (Teige et al., 2003) and that conditional IFNAR-KO in myeloid cells or GR-KO in hematopoietic cells also leads to more severe disease and enhanced lethality, lending genetic support to therapeutic efficacy of IFN-β in EAE and MS (Prinz et al., 2008; Wüst et al., 2008). The gene discussed is IFNB1; the disease is myeloid sarcoma.